MY209340A - Egfr inhibitor for the treatment of cancer - Google Patents

Egfr inhibitor for the treatment of cancer

Info

Publication number
MY209340A
MY209340A MYPI2021007566A MYPI2021007566A MY209340A MY 209340 A MY209340 A MY 209340A MY PI2021007566 A MYPI2021007566 A MY PI2021007566A MY PI2021007566 A MYPI2021007566 A MY PI2021007566A MY 209340 A MY209340 A MY 209340A
Authority
MY
Malaysia
Prior art keywords
cancer
treatment
egfr inhibitor
compound
figures
Prior art date
Application number
MYPI2021007566A
Inventor
Alice Nagel Yvonne
Hewings David
Dolente Cosimo
Steiner Sandra
Rueher Daniel
Ricci Antonio
Obst Sander Ulrike
Kuhn Bernd
Jaeschke Georg
Goergler Annick
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of MY209340A publication Critical patent/MY209340A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/485—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Inorganic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

The invention provides novel a compound having the general formula (I) as described herein, compositions including the compound and methods of using the compound. [No Figures]
MYPI2021007566A 2019-06-21 2020-06-19 Egfr inhibitor for the treatment of cancer MY209340A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP19181754 2019-06-21
PCT/EP2020/067076 WO2020254562A1 (en) 2019-06-21 2020-06-19 Egfr inhibitor for the treatment of cancer

Publications (1)

Publication Number Publication Date
MY209340A true MY209340A (en) 2025-07-03

Family

ID=67139601

Family Applications (1)

Application Number Title Priority Date Filing Date
MYPI2021007566A MY209340A (en) 2019-06-21 2020-06-19 Egfr inhibitor for the treatment of cancer

Country Status (31)

Country Link
US (5) US12479849B2 (en)
EP (4) EP3986896B1 (en)
JP (4) JP7550800B2 (en)
KR (1) KR102913816B1 (en)
CN (4) CN113993872B (en)
AR (4) AR119209A1 (en)
AU (1) AU2020295703B2 (en)
BR (1) BR112021025445B1 (en)
CA (1) CA3140485A1 (en)
CL (1) CL2021003408A1 (en)
CO (1) CO2021017173A2 (en)
CR (1) CR20210624A (en)
DK (1) DK3986897T3 (en)
ES (1) ES2961187T3 (en)
FI (1) FI3986897T3 (en)
HR (1) HRP20231276T1 (en)
HU (1) HUE063676T2 (en)
IL (1) IL288522B2 (en)
LT (1) LT3986897T (en)
MA (1) MA56508B1 (en)
MX (1) MX2021015464A (en)
MY (1) MY209340A (en)
PE (1) PE20220576A1 (en)
PH (1) PH12021553190A1 (en)
PL (1) PL3986897T3 (en)
PT (1) PT3986897T (en)
RS (1) RS64720B1 (en)
SI (1) SI3986897T1 (en)
TW (4) TW202115072A (en)
UA (1) UA129328C2 (en)
WO (4) WO2020254572A1 (en)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW202115073A (en) * 2019-06-21 2021-04-16 瑞士商赫孚孟拉羅股份公司 New egfr inhibitors
ES2961187T3 (en) 2019-06-21 2024-03-08 Hoffmann La Roche EGFR inhibitor for cancer treatment
AU2020383423B2 (en) 2019-11-11 2026-06-18 Dana-Farber Cancer Institute, Inc. Allosteric EGFR inhibitors and methods of use thereof
IL303064A (en) 2020-12-01 2023-07-01 Hoffmann La Roche New indazole acetylene derivatives
JP7798887B2 (en) * 2020-12-01 2026-01-14 エフ・ホフマン-ラ・ロシュ・アクチェンゲゼルシャフト Novel indazole derivatives
CN116507328A (en) 2020-12-01 2023-07-28 豪夫迈·罗氏有限公司 New Indazole Derivatives
CN117440813A (en) * 2021-05-26 2024-01-23 C4医药公司 EGFR-degrading agents for the treatment of cancer metastasis to the brain or CNS
BR112023024507A2 (en) * 2021-05-26 2024-02-15 C4 Therapeutics Inc METHOD FOR TREATING A MUTANT EPIDERMAL GROWTH FACTOR RECEPTOR-MEDIATED CANCER THAT HAS METASTASIS TO THE BRAIN OR CENTRAL NERVOUS SYSTEM
EP4522113A1 (en) * 2022-05-13 2025-03-19 F. Hoffmann-La Roche AG Combination of allosteric and orthosteric egfr inhibitors for the treatment of cancer
JP2025515833A (en) * 2022-05-13 2025-05-20 エフ・ホフマン-ラ・ロシュ・アクチェンゲゼルシャフト New indazole derivatives
CN121487738A (en) 2023-03-30 2026-02-06 锐新医药公司 Compositions for inducing RAS GTP hydrolysis and their uses
KR20260019479A (en) 2023-05-04 2026-02-10 레볼루션 메디슨즈, 인크. Combination therapy for RAS-related diseases or disorders
CN121889155A (en) 2023-08-07 2026-04-17 锐新医药公司 RMC-6291 for the treatment of RAS protein-related diseases or disorders
AU2024360465A1 (en) 2023-10-12 2026-04-09 Revolution Medicines, Inc. Macrocyclic ras inhibitors
WO2025171296A1 (en) 2024-02-09 2025-08-14 Revolution Medicines, Inc. Ras inhibitors
WO2025240847A1 (en) 2024-05-17 2025-11-20 Revolution Medicines, Inc. Ras inhibitors
US20250375445A1 (en) 2024-06-07 2025-12-11 Revolution Medicines, Inc. Methods of treating a ras protein-related disease or disorder
WO2025265060A1 (en) 2024-06-21 2025-12-26 Revolution Medicines, Inc. Therapeutic compositions and methods for managing treatment-related effects
WO2026006747A1 (en) 2024-06-28 2026-01-02 Revolution Medicines, Inc. Ras inhibitors
WO2026015790A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026015801A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026015825A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Use of ras inhibitor for treating pancreatic cancer
WO2026015796A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026050446A1 (en) 2024-08-29 2026-03-05 Revolution Medicines, Inc. Ras inhibitors
WO2026072904A2 (en) 2024-09-26 2026-04-02 Revolution Medicines, Inc. Compositions and methods for treating lung cancer
WO2026090116A2 (en) 2024-10-21 2026-04-30 Revolution Medicines, Inc. Ras inhibitors
US20260108528A1 (en) 2024-10-22 2026-04-23 Revolution Medicines, Inc. Methods of treating a ras protein-related disease or disorder
WO2026090245A1 (en) 2024-10-22 2026-04-30 Revolution Medicines, Inc. Use of ras inhibitors for treating cancer
WO2026106912A1 (en) 2024-11-12 2026-05-21 Revolution Medicines, Inc. Ras inhibitors
WO2026112260A1 (en) 2024-11-21 2026-05-28 Revolution Medicines, Inc. Ras inhibitors
WO2026122764A2 (en) 2024-12-06 2026-06-11 Revolution Medicines, Inc. Ras inhibitors
WO2026128688A2 (en) 2024-12-13 2026-06-18 Revolution Medicines, Inc. Ras inhibitors
WO2026161839A1 (en) 2025-01-27 2026-07-30 Revolution Medicines, Inc. Ras inhibitors

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0508715D0 (en) * 2005-04-29 2005-06-08 Astrazeneca Ab Chemical compounds
CN101273033A (en) * 2005-09-20 2008-09-24 阿斯利康(瑞典)有限公司 4-(1H-Indol-5-yl-amino)-quinazoline compounds as ERBB receptor tyrosine kinase inhibitors for the treatment of cancer
US20110212078A1 (en) 2008-06-25 2011-09-01 Reddy Panduranga Adulla P Synthesis and use of heterocyclic antibacterial agents
US8420661B2 (en) 2010-04-13 2013-04-16 Hoffmann-La Roche Inc. Arylethynyl derivatives
LT2964638T (en) 2013-03-06 2017-12-27 Astrazeneca Ab Quinazoline inhibitors of activating mutant forms of epidermal growth factor receptor
WO2015095807A1 (en) * 2013-12-20 2015-06-25 Biomed Valley Discoveries, Inc. Cancer treatments using combinations of egfr and erk inhibitors
CN105777756B (en) * 2014-07-02 2019-03-01 广东东阳光药业有限公司 Heteroaromatic compounds and their application in medicine
JP6639497B2 (en) * 2014-11-10 2020-02-05 ジェネンテック, インコーポレイテッド Bromodomain inhibitors and uses thereof
KR102616818B1 (en) 2015-05-14 2023-12-22 더 위스타 인스티튜트 오브 아나토미 앤드 바이올로지 EBNA1 inhibitors and methods of their use
HK1252693A1 (en) 2015-06-30 2019-05-31 Dana Farber Cancer Institute, Inc. Inhibitors of egfr and methods of use thereof
TW201834651A (en) 2016-12-22 2018-10-01 瑞士商赫孚孟拉羅股份公司 Compounds
ES2927480T3 (en) 2017-06-02 2022-11-07 Hoffmann La Roche Isoindoline-acetylene compounds for cancer treatment
WO2018220149A1 (en) * 2017-06-02 2018-12-06 F. Hoffmann-La Roche Ag Compounds
WO2019046668A1 (en) * 2017-08-31 2019-03-07 Kezar Life Sciences Amide substituted thiazoles as protein secretion inhibitors
IL279800B2 (en) 2018-06-29 2024-02-01 Hoffmann La Roche Selective allosteric inhibitors of epidermal growth factor receptor mutants, pharmaceutical compositions comprising them and use thereof
ES2961187T3 (en) 2019-06-21 2024-03-08 Hoffmann La Roche EGFR inhibitor for cancer treatment
US20220315577A1 (en) 2019-06-21 2022-10-06 Hoffmann-La Roche Inc. New egfr inhibitors
TW202115073A (en) 2019-06-21 2021-04-16 瑞士商赫孚孟拉羅股份公司 New egfr inhibitors
AR120800A1 (en) 2019-12-20 2022-03-16 Hoffmann La Roche 6,7-DIHYDRO-5H-PYRROLO[1,2-C]IMIDAZOLE DERIVATIVES AS EGFR INHIBITORS
AR120799A1 (en) 2019-12-20 2022-03-16 Hoffmann La Roche 2-[4-CHLORO-6-[2-[4-[[4-(HYDROXYMETHYL)-1-PIPERIDYL]METHYL]PHENYL]ETHYNYL]-1-OXOISOINDOLIN-2-IL]-2-(6,7- DIHYDRO-5H-PYRROLO[1,2-C]IMIDAZOL-1-IL)-N-TIAZOL-2-IL-ACETAMIDE AS EGFR INHIBITOR
CN116507328A (en) 2020-12-01 2023-07-28 豪夫迈·罗氏有限公司 New Indazole Derivatives
JP7798887B2 (en) 2020-12-01 2026-01-14 エフ・ホフマン-ラ・ロシュ・アクチェンゲゼルシャフト Novel indazole derivatives
IL303064A (en) 2020-12-01 2023-07-01 Hoffmann La Roche New indazole acetylene derivatives
JP2025515833A (en) 2022-05-13 2025-05-20 エフ・ホフマン-ラ・ロシュ・アクチェンゲゼルシャフト New indazole derivatives
EP4522113A1 (en) 2022-05-13 2025-03-19 F. Hoffmann-La Roche AG Combination of allosteric and orthosteric egfr inhibitors for the treatment of cancer

Also Published As

Publication number Publication date
US20230054473A1 (en) 2023-02-23
CN113993872B (en) 2024-09-24
RS64720B1 (en) 2023-11-30
TW202115071A (en) 2021-04-16
CN113993872A (en) 2022-01-28
US20250289824A1 (en) 2025-09-18
PH12021553190A1 (en) 2022-11-07
AU2020295703B2 (en) 2026-02-12
CR20210624A (en) 2022-02-14
JP2022538403A (en) 2022-09-02
EP3986898A1 (en) 2022-04-27
KR102913816B1 (en) 2026-01-16
TW202115074A (en) 2021-04-16
EP3986898B1 (en) 2023-03-15
JP7530391B2 (en) 2024-08-07
CN114008049B (en) 2024-07-05
MA56508A (en) 2022-04-27
EP3986896B1 (en) 2023-03-15
JP2022537769A (en) 2022-08-29
MX2021015464A (en) 2022-01-24
EP3986895B1 (en) 2023-03-15
JP7550800B2 (en) 2024-09-13
BR112021025445A2 (en) 2022-02-01
WO2020254572A1 (en) 2020-12-24
CA3140485A1 (en) 2020-12-24
US20220315592A1 (en) 2022-10-06
KR20220024105A (en) 2022-03-03
CN113993873A (en) 2022-01-28
TW202115072A (en) 2021-04-16
CO2021017173A2 (en) 2022-01-17
AR119208A1 (en) 2021-12-01
HRP20231276T1 (en) 2024-02-02
WO2020254562A1 (en) 2020-12-24
WO2020254565A1 (en) 2020-12-24
TW202115053A (en) 2021-04-16
US12479849B2 (en) 2025-11-25
CN113993873B (en) 2024-08-02
US20220315593A1 (en) 2022-10-06
EP3986896A1 (en) 2022-04-27
AR119210A1 (en) 2021-12-01
JP7550798B2 (en) 2024-09-13
LT3986897T (en) 2023-11-10
IL288522A (en) 2022-01-01
SI3986897T1 (en) 2023-12-29
CN114008049A (en) 2022-02-01
US20220135571A1 (en) 2022-05-05
CN113966335A (en) 2022-01-21
IL288522B2 (en) 2025-02-01
AR119206A1 (en) 2021-12-01
JP2022538055A (en) 2022-08-31
CL2021003408A1 (en) 2022-10-14
UA129328C2 (en) 2025-03-19
JP7550799B2 (en) 2024-09-13
DK3986897T3 (en) 2023-10-30
EP3986895A1 (en) 2022-04-27
AR119209A1 (en) 2021-12-01
JP2022537191A (en) 2022-08-24
TWI869416B (en) 2025-01-11
CN113966335B (en) 2024-08-02
FI3986897T3 (en) 2023-10-20
PE20220576A1 (en) 2022-04-20
AU2020295703A1 (en) 2022-01-06
BR112021025445B1 (en) 2024-02-27
MA56508B1 (en) 2023-11-30
ES2961187T3 (en) 2024-03-08
US12344613B2 (en) 2025-07-01
WO2020254568A1 (en) 2020-12-24
EP3986897A1 (en) 2022-04-27
HUE063676T2 (en) 2024-01-28
PT3986897T (en) 2023-10-23
EP3986897B1 (en) 2023-08-30
IL288522B1 (en) 2024-10-01
PL3986897T3 (en) 2024-01-22

Similar Documents

Publication Publication Date Title
PH12021553018A1 (en) New egfr inhibitors
MX2025003398A (en) Novel tetraheterocycle compound
CR20220354A (en) Inhibitors of mutant forms of egfr
PH12022551503A1 (en) Kras mutant protein inhibitors
MX2021014441A (en) Tead inhibitors and uses thereof.
JOP20220142A1 (en) Kras g12c inhibitors
MX2021003843A (en) Inhibitors of the yap/taz-tead interaction and their use in the treatment of cancer.
ZA202005326B (en) Heteroaryl compounds as type ii irak inhibitors and uses hereof
ZA202206923B (en) New methylquinazolinone derivatives
MX2023005160A (en) Substituted 4-aminoisoindoline-1,3-dione compounds and their use for treating lymphoma.
EA202193015A1 (en) CDK INHIBITORS
ZA202100485B (en) Pyrimidine compounds and pharmaceutical compositions for preventing or treating cancers including the same
PH12021553233A1 (en) Imidazopyrimidines as eed inhibitors and the use thereof
EP4477220A3 (en) Plasma kallikrein inhibitors and uses thereof
MX2021014531A (en) Substituted aminopurine compounds, compositions thereof, and methods of treatment therewith.
PH12022550471A1 (en) Heterocyclic compounds
PH12022550491A1 (en) Perk inhibiting pyrrolopyrimidine compounds
PH12022550130A1 (en) Enzyme inhibitors
PH12022551241A1 (en) Egfr inhibitors
PH12021553249A1 (en) New heterocyclic compounds
PH12022550497A1 (en) Perk inhibiting compounds
EP4438127A3 (en) Inhibiting ataxia telangiectasia and rad3-related protein (atr)
EP4706394A3 (en) Use of alkoxypyrazoles as nitrification inhibitors
MX2022006776A (en) Ophthalmic pharmaceutical compositions.
ZA202205170B (en) Process and intermediate for the preparation of oxetan-2-ylmethanamine